Boston-based pharmaceutical company Ratio Therapeutics has entered a long-term, multi-isotope supply agreement with Nusano to boost production of its cancer radiopharmaceuticals.
Under the agreement, Nusano will supply Ratio with copper-64 for developing PET imaging agents and lutetium-177 and actinium-225 for developing targeted therapies. Both companies have production facilities miles apart in Utah’s Salt Lake Valley, which will streamline the logistics involved in scale-up and delivery, Ratio said.
Ratio’s product pipeline includes a fibroblast activation protein (FAP)-targeted PET radiotracer for imaging soft tissue sarcoma, which is expected to enter the clinic this year, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
